Eliglustat plus CD30 immunotherapy for CD30+ lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two medicines (eliglustat and a CD30-targeted immunotherapy) for people with a type of lymphoma that has a specific marker called CD30. It aims to see if this combination can help when standard treatments have already been used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lymphoma cells must have a specific marker called CD30 (your doctor can confirm this).
- You must be between 18 and 75 years old.
- You should be well enough to do most of your daily activities (score 0 or 1 on a standard scale).
- You must have had at least one previous cancer treatment (like chemo or immunotherapy).
- You should not be taking certain other medications that could interfere with the study drugs – your study team will check this.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies an experimental treatment that targets a marker called CD30 on cancer cells. It is for adults with certain relapsed or refractory CD30-positive blood cancers to see how well the treatment works and what side effects it causes.
This Phase 2 study tests two medicines—glofitamab and polatuzumab—together with chemotherapy to treat newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) that has the CD20 marker. It aims to improve how well the lymphoma responds and how long responses last.
This study tests a new drug (IMM0306) combined with lenalidomide, compared to a placebo with lenalidomide, for people with follicular lymphoma that has come back or not responded to treatment. The goal is to see if adding IMM0306 helps control the cancer better.
This trial tests a new type of immune cell therapy for CD30-positive lymphomas. The cells are made from donated blood and are designed to find and attack your cancer.
This trial tests a new type of immunotherapy called CD30 CAR-T cells for people with CD30-positive lymphoma that has come back or hasn't responded to other treatments. The treatment uses your own immune cells that are specially trained to find and kill lymphoma cells carrying the CD30 marker.
This trial tests two drugs, glofitamab and selinexor, for patients with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least two previous treatments. The goal is to see if this combination can help control the cancer.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.